D
Cognition Therapeutics, Inc.
CGTX
$0.3529
$0.033510.49%
D
Sell
2/18/2025Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 2/18/2025 due to an increase in the total return index and volatility index.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 2/18/2025 due to an increase in the total return index and volatility index.
E
Sell
1/31/2025Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 1/31/2025 due to a decline in the volatility index.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 1/31/2025 due to a decline in the volatility index.
D
Sell
1/10/2025Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 1/10/2025 due to an increase in the volatility index.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 1/10/2025 due to an increase in the volatility index.
E
Sell
9/24/2024Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 9/24/2024 due to a decline in the total return index and volatility index.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 9/24/2024 due to a decline in the total return index and volatility index.
D
Sell
9/9/2024Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 9/9/2024 due to an increase in the volatility index.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 9/9/2024 due to an increase in the volatility index.
E
Sell
8/22/2024Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 8/22/2024 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 3.74 to 2.9.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 8/22/2024 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 3.74 to 2.9.
D
Sell
8/5/2024Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 8/5/2024 due to an increase in the volatility index.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 8/5/2024 due to an increase in the volatility index.
E
Sell
7/17/2024Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 7/17/2024 due to a decline in the volatility index.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 7/17/2024 due to a decline in the volatility index.
D
Sell
6/28/2024Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 6/28/2024 due to an increase in the volatility index.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 6/28/2024 due to an increase in the volatility index.
E
Sell
6/11/2024Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 6/11/2024 due to a decline in the total return index and volatility index.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 6/11/2024 due to a decline in the total return index and volatility index.
D
Sell
5/22/2024Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 5/22/2024 due to an increase in the solvency index, volatility index and total return index. Debt to equity declined from 0.03 to 0.02, and the quick ratio increased from 3.07 to 3.74.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 5/22/2024 due to an increase in the solvency index, volatility index and total return index. Debt to equity declined from 0.03 to 0.02, and the quick ratio increased from 3.07 to 3.74.
E
Sell
5/3/2024Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 5/3/2024 due to a decline in the volatility index and growth index.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 5/3/2024 due to a decline in the volatility index and growth index.
D
Sell
4/18/2024Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 4/18/2024 due to an increase in the volatility index and solvency index.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 4/18/2024 due to an increase in the volatility index and solvency index.
E
Sell
4/1/2024Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 4/1/2024 due to a decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.01 to 0.03.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 4/1/2024 due to a decline in the total return index, solvency index and volatility index. Debt to equity increased from 0.01 to 0.03.
D
Sell
3/19/2024Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 3/19/2024 due to a noticeable increase in the total return index and volatility index.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 3/19/2024 due to a noticeable increase in the total return index and volatility index.
E
Sell
2/29/2024Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 2/29/2024 due to a decline in the volatility index.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 2/29/2024 due to a decline in the volatility index.
D
Sell
2/9/2024Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 2/9/2024 due to an increase in the volatility index and total return index.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 2/9/2024 due to an increase in the volatility index and total return index.
E
Sell
1/25/2024Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 1/25/2024 due to a decline in the volatility index and valuation index.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 1/25/2024 due to a decline in the volatility index and valuation index.
D
Sell
12/14/2023Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 12/14/2023 due to an increase in the volatility index.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 12/14/2023 due to an increase in the volatility index.
E
Sell
9/28/2023Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 9/28/2023 due to a decline in the total return index and volatility index.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 9/28/2023 due to a decline in the total return index and volatility index.
D
Sell
9/13/2023Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 9/13/2023 due to an increase in the volatility index.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 9/13/2023 due to an increase in the volatility index.
E
Sell
8/28/2023Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 8/28/2023 due to a decline in the volatility index.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 8/28/2023 due to a decline in the volatility index.
D
Sell
8/10/2023Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 8/10/2023 due to an increase in the volatility index, growth index and solvency index. Debt to equity declined from 0.02 to 0.01, and earnings per share increased from -$0.2121 to -$0.16.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 8/10/2023 due to an increase in the volatility index, growth index and solvency index. Debt to equity declined from 0.02 to 0.01, and earnings per share increased from -$0.2121 to -$0.16.
E
Sell
7/31/2023Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 7/31/2023 due to a decline in the volatility index.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 7/31/2023 due to a decline in the volatility index.
D
Sell
7/11/2023Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 7/11/2023 due to an increase in the volatility index and valuation index.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 7/11/2023 due to an increase in the volatility index and valuation index.
E
Sell
6/23/2023Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 6/23/2023 due to a decline in the volatility index and valuation index.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 6/23/2023 due to a decline in the volatility index and valuation index.
D
Sell
6/2/2023Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 6/2/2023 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 73.44% from -$10.18M to -$2.71M, and EBIT increased 3.52% from -$9.3M to -$8.97M.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 6/2/2023 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 73.44% from -$10.18M to -$2.71M, and EBIT increased 3.52% from -$9.3M to -$8.97M.
E
Sell
3/14/2023Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 2/8/2023 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 7.2 to 4.06, earnings per share declined from -$0.2546 to -$0.2877, and EBIT declined 3.37% from -$12.21M to -$12.63M.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E+ from D- on 2/8/2023 due to a noticeable decline in the growth index, solvency index and volatility index. The quick ratio declined from 7.2 to 4.06, earnings per share declined from -$0.2546 to -$0.2877, and EBIT declined 3.37% from -$12.21M to -$12.63M.
D
Sell
7/1/2022Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E on 7/1/2022 due to an increase in the volatility index, solvency index and growth index. Earnings per share increased from -$0.3969 to -$0.1711, and EBIT increased 20.28% from -$11.81M to -$9.41M.
Cognition Therapeutics, Inc. (CGTX) was upgraded to D- from E on 7/1/2022 due to an increase in the volatility index, solvency index and growth index. Earnings per share increased from -$0.3969 to -$0.1711, and EBIT increased 20.28% from -$11.81M to -$9.41M.
E
Sell
4/1/2022Upgraded
Cognition Therapeutics, Inc. (CGTX) was upgraded to E from E- on 4/1/2022 due to a significant increase in the solvency index and growth index. The quick ratio increased from 2.14 to 7.25, operating cash flow increased 104.93% from -$2.05M to $101, and earnings per share increased from -$8.1235 to -$0.3969.
Cognition Therapeutics, Inc. (CGTX) was upgraded to E from E- on 4/1/2022 due to a significant increase in the solvency index and growth index. The quick ratio increased from 2.14 to 7.25, operating cash flow increased 104.93% from -$2.05M to $101, and earnings per share increased from -$8.1235 to -$0.3969.
E
Sell
1/3/2022None
Cognition Therapeutics, Inc. (CGTX) was downgraded to E- from U on 01/03/2022.
Cognition Therapeutics, Inc. (CGTX) was downgraded to E- from U on 01/03/2022.
NASDAQ
04/11/2025 4:00PM Eastern
Quotes delayed
